![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/en/news-release/2024/07/09/2910486/0/en/Curium-Submits-New-Drug-Application-for-Lutetium-Lu-177-Dotatate-Injection.html
https://www.globenewswire.com/news-release/2024/06/05/2893669/0/en/Curium-Adds-the-Institut-Laue-Langevin-Reactor-to-Global-Irradiation-Portfolio-to-Ensure-Continuous-Supply-of-Lutetium-177-to-Benefit-More-Than-100-000-Cancer-Patients-Over-the-Nex.html
https://www.globenewswire.com/news-release/2024/05/30/2890440/0/en/Curium-Announces-First-Commercial-Doses-in-France-of-Pylclari-an-Innovative-18F-Psma-Pet-Tracer-Indicated-in-Patients-With-Prostate-Cancer.html
https://www.globenewswire.com/news-release/2024/05/29/2889578/0/en/Curium-Extends-Irradiation-Partnership-With-NRG-I-PALLAS-in-Netherlands-for-Continuous-Supply-of-Lutetium-177-to-Treat-1-000s-of-Cancer-Patients-Each-Year.html
https://www.globenewswire.com/news-release/2024/05/06/2875596/0/en/Curium-Announces-First-Commercial-Doses-in-Germany-of-PYLCLARI-An-Innovative-18F-PSMA-PET-Tracer-Indicated-in-Patients-With-Prostate-Cancer.html
https://www.globenewswire.com/news-release/2024/04/23/2867314/0/en/Curium-Enrolls-First-Prostate-Cancer-Patients-in-its-Phase-3-SOLAR-Trials.html
https://www.globenewswire.com//news-release/2024/02/06/2824070/0/en/Curium-Announces-Ioflupane-I-123-Injection-Availability-for-Friday-Patient-Use.html
https://www.prnewswire.com/news-releases/curasight-as-achieves-first-milestone-under-collaboration-with-curium-inc-302040336.html
https://www.globenewswire.com//news-release/2023/11/23/2785241/0/en/Curium-Completes-Patient-Enrollment-of-Phase-3-ECLIPSE-Trial-Ahead-of-Schedule.html
https://www.globenewswire.com/news-release/2023/08/15/2725665/0/en/Curium-Announces-Achievement-of-Co-Primary-Endpoints-in-Phase-2-of-Its-Phase-1-2-SOLAR-Clinical-Trial-Imaging-Men-With-Histologically-Proven-Prostate-Cancer-Using-Copper-Cu-64-PSMA.html